Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

NCT06419634 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

105

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia
Myelodysplastic Syndrome

Interventions

DRUG: BMS-986497
DRUG: Azacitidine
DRUG: Venetoclax

Sponsor

Bristol-Myers Squibb